Abstract
Leukemia inhibitory factor (LIF) is identified as a critical local regulator in the human pituitary gland, where it stimulates the synthesis and secretion of adrenocorticotropin hormone (ACTH). This study demonstrates that LIF is expressed in human fetal and adult pituitary tissues, predominantly within corticotrophs. By acting as an autocrine and paracrine signal, LIF helps determine cell identity during fetal development and modulates the hormonal response to stress in adults. These findings suggest an intrapituitary role for LIF in both embryonic determination and the regulation of mature ACTH secretion.
Introduction
The classic model of the endocrine system describes a top-down hierarchy where the hypothalamus releases signals, such as corticotropin-releasing hormone (CRH), to trigger the pituitary's release of hormones like ACTH. However, this model does not fully account for how the pituitary fine-tunes its output or develops its complex cellular architecture. This research investigates the "intrapituitary" environment, specifically focusing on whether cytokines like Leukemia Inhibitory Factor (LIF) play a role in local growth and functional regulation.
Methods and Molecular Mapping
The study utilized a multi-pronged approach involving human fetal pituitary tissue (14–27 weeks gestation), normal adult pituitaries, and various pituitary adenomas. To detect LIF mRNA transcripts, researchers employed RNase protection assays across multiple tissue types.
In addition to molecular mapping, the team used immunohistochemistry and immunoelectron microscopy to pinpoint the cellular localization of LIF protein. Mechanistic studies were conducted using the AtT-20 murine cell line to test how LIF and the related peptide Oncostatin M (OSM) affected the expression of the POMC gene (the precursor to ACTH) and ACTH secretion.
Key Results and Insights
Cellular Localization and Development
LIF expression was detected as early as 14 weeks of gestation, a critical window for pituitary cell differentiation. In fetal tissue, LIF immunoreactivity colocalized with approximately 30% of ACTH-expressing cells and 20% of somatotrophs. Immunoelectron microscopy further revealed that LIF is stored within secretory granules, supporting its role in regulated paracrine or autocrine secretion.
Functional Regulation of ACTH
Functional assays demonstrated that LIF is a potent stimulator of the stress hormone axis:
- Gene Stimulation: In AtT-20 cells, LIF (ED50 10 pM) increased basal POMC mRNA levels by 40%.
- Hormone Secretion: LIF and OSM boosted CRH-induced ACTH secretion by two- to threefold.
- Autocrine Feedback: The addition of an anti-LIF antiserum decreased basal ACTH secretion, proving that pituitary cells use locally produced LIF to stimulate their own activity via an autocrine loop.
- The gp130 Receptor: Because LIF and OSM share the gp130 receptor subunit, their effects were not additive, confirming they operate through a common signaling pathway.
Clinical Implications and Tumor Specificity
The study found that LIF was strongly expressed in ACTH- and growth hormone (GH)-producing adenomas but was absent in non-functioning pituitary tumors. This suggests that LIF may drive the pathological overproduction of hormones in conditions such as Cushing’s disease.
While the study establishes LIF as a key regulator, future work is needed to map the exact intracellular signaling pathways between the gp130 receptor and the POMC gene promoter. Additionally, investigating LIF's role during systemic inflammation may explain how the body maintains high ACTH levels during severe illness when hypothalamic signals might be suppressed.
Summary updated